SCHEMBL17059658

SCHEMBL17059658

Nc1cccc(NC(=O)Nc2ccnc(Nc3ccc(F)c(Cl)c3)n2)c1

nearest known ligand 0.58

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
CSNK1A1 P48729 1/20 0.58
MEN1 O00255 2/20 0.54
LMNA P02545 2/20 0.54
KMT2A Q03164 2/20 0.54
TP53 P04637 1/20 0.54
HTT P42858 1/20 0.54
CDK8 P49336 1/20 0.49
MAPT P10636 1/20 0.49
EGFR P00533 4/20 0.48
AURKA O14965 2/20 0.48
AURKB Q96GD4 1/20 0.48
MAPK1 P28482 1/20 0.47
SLC2A1 P11166 1/20 0.47
L3MBTL1 Q9Y468 1/20 0.47
XBP1 P17861 1/20 0.46
STAT3 P40763 1/20 0.46
GSK3A P49840 1/20 0.46
GSK3B P49841 1/20 0.46
CDK5 Q00535 1/20 0.46
CDK5R1 Q15078 1/20 0.46

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL17059660 0.85 EGFR (0.68) CSNK1A1EGFR
SCHEMBL17059657 0.85 KMT2A (0.54) CSNK1A1MEN1LMNAKMT2ATP53
SCHEMBL17059641 0.83 EGFR (0.55) EGFR
SCHEMBL5572683 0.82 DDX3X (0.68) MEN1LMNAKMT2ATP53HTT
SCHEMBL17059600 0.80 EGFR (0.74) MEN1LMNAKMT2ATP53MAPT
SCHEMBL17059591 0.78 DDX3X (0.60) MEN1LMNAKMT2ATP53HTT
SCHEMBL17059610 0.77 EGFR (0.64) EGFR
SCHEMBL657412 0.76 MAPK1 (0.62) MEN1LMNAKMT2AMAPTEGFR
SCHEMBL17059682 0.75 EGFR (0.76) EGFR
SCHEMBL1519005 0.74 CNR1 (0.64) MEN1LMNAKMT2ATP53HTT

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2015127873-A1 ARYLAMINO PYRAMIDINE COMPOUND AND APPLICATION THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM 上海海雁医药科技有限公司 2015-09-03 WO disclosed